162 related articles for article (PubMed ID: 23679901)
1. Is tigecycline drug of choice for cIAI and cSSTI?
Hosgor-Limoncu M
Int J Clin Pract; 2013 Jun; 67(6):492-3. PubMed ID: 23679901
[No Abstract] [Full Text] [Related]
2. Clinical and microbiological efficacy of tigecycline for complicated skin-soft-tissue and intra-abdominal infections in a Turkish university hospital.
Avkan-Oguz V; Yapar N; Alp-Cavus S; Demir Onder K; Aktas E; Gulay Z; Cakır N
Int J Clin Pract; 2013 Jun; 67(6):505-11. PubMed ID: 23679904
[TBL] [Abstract][Full Text] [Related]
3. Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials.
Bassetti M; McGovern PC; Wenisch C; Meyer RD; Yan JL; Wible M; Rottinghaus ST; Quintana A
Int J Antimicrob Agents; 2015 Sep; 46(3):346-50. PubMed ID: 26155003
[TBL] [Abstract][Full Text] [Related]
4. Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies.
Heizmann WR; Dupont H; Montravers P; Guirao X; Eckmann C; Bassetti M; García MS; Capparella MR; Simoneau D; Bodmann KF
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii45-55. PubMed ID: 23772046
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies.
Guirao X; Sánchez García M; Bassetti M; Bodmann KF; Dupont H; Montravers P; Heizmann WR; Capparella MR; Simoneau D; Eckmann C
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii37-44. PubMed ID: 23772045
[TBL] [Abstract][Full Text] [Related]
6. Tigecycline: an antibiotic for the twenty-first century.
Dryden M
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii3-4. PubMed ID: 23772044
[TBL] [Abstract][Full Text] [Related]
7. An essential requirement for the licensing of new antibiotics is the provision of data on efficacy and safety obtained from clinical trials in which patients are randomized to receive either the experimental drug or a comparator antibiotic regarded as a standard treatment option. Preface.
Johnson AP; Leibovici L
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii1. PubMed ID: 23930279
[No Abstract] [Full Text] [Related]
8. Influence of age on the clinical efficacy of tigecycline in severely ill patients.
Bassetti M; Guirao X; Montravers P; Rossolini GM; Sánchez García M; Sganga G; Eckmann C
J Glob Antimicrob Resist; 2019 Sep; 18():199-206. PubMed ID: 30953830
[TBL] [Abstract][Full Text] [Related]
9. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities.
Bodmann KF; Heizmann WR; von Eiff C; Petrik C; Löschmann PA; Eckmann C
Chemotherapy; 2012; 58(4):282-94. PubMed ID: 23052187
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies.
Montravers P; Bassetti M; Dupont H; Eckmann C; Heizmann WR; Guirao X; García MS; Capparella MR; Simoneau D; Bodmann KF
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii15-24. PubMed ID: 23772042
[TBL] [Abstract][Full Text] [Related]
11. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies.
Bassetti M; Eckmann C; Bodmann KF; Dupont H; Heizmann WR; Montravers P; Guirao X; Capparella MR; Simoneau D; Sánchez García M
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii5-14. PubMed ID: 23772047
[TBL] [Abstract][Full Text] [Related]
12. Tigecycline in the Treatment of Patients with Necrotizing Skin and Soft Tissue Infections Due to Multiresistant Bacteria.
Eckmann C; Heizmann W; Bodmann KF; von Eiff C; Petrik C; Loeschmann PA
Surg Infect (Larchmt); 2015 Oct; 16(5):618-25. PubMed ID: 26115414
[TBL] [Abstract][Full Text] [Related]
13. [Tigecycline: a systematic review of clinical experience during first years of prescription].
Diomedi P A
Rev Chilena Infectol; 2009 Apr; 26(2):114-25. PubMed ID: 19621142
[TBL] [Abstract][Full Text] [Related]
14. Tigecycline: an update.
Stein GE; Babinchak T
Diagn Microbiol Infect Dis; 2013 Apr; 75(4):331-6. PubMed ID: 23357291
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of tigecycline in complicated skin and skin structure infections and complicated intra-abdominal infections.
Wilcox MH
J Chemother; 2005 Aug; 17 Suppl 1():23-9. PubMed ID: 16285355
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections.
Grolman DC
Int J Infect Dis; 2007 May; 11 Suppl 1():S7-15. PubMed ID: 17603950
[TBL] [Abstract][Full Text] [Related]
17. Anti-anaerobic activity of serum from patients treated with tigecycline for skin/soft tissue infections.
Stein GE; Tyrrell KL; Dybas LA; Citron DM; Nicolau DP; Goldstein EJ
Anaerobe; 2011 Aug; 17(4):213-5. PubMed ID: 21376823
[TBL] [Abstract][Full Text] [Related]
18. Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice.
Eckmann C; Heizmann WR; Leitner E; von Eiff C; Bodmann KF
Chemotherapy; 2011; 57(4):275-84. PubMed ID: 21778715
[TBL] [Abstract][Full Text] [Related]
19. Tigecycline: a new antibiotic.
Hylands J
Intensive Crit Care Nurs; 2008 Aug; 24(4):260-3. PubMed ID: 18554910
[TBL] [Abstract][Full Text] [Related]
20. Establishing the role of tigecycline in an era of antimicrobial resistance.
Schafer JJ; Goff DA
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
